Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

885

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Hypertension
Interventions
DRUG

Azilsartan medoxomil

Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 40 mg, tablets, orally, once daily for up to 22 weeks.

DRUG

Azilsartan medoxomil

Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 80 mg, tablets, orally, once daily for up to 22 weeks.

DRUG

Ramipril

Ramipril 2.5 mg, tablets, orally, once daily for two weeks; then increased to 10 mg, tablets, orally, once daily for up to 22 weeks.

Trial Locations (72)

Unknown

Pleven

Plovdiv

Rousse

Sofia

Varna

Paide

Tallinn

Tartu

Viljandi

Joensuu

Mikkeli

Tampere

Turku

Augsburg

Bad Krozingen

Bad Segeberg

Berlin

Cologne

Dortmund

Dresden

Essen

Frankfurt

Goch

Großheirath

Hamburg

Karlsruhe

Künzing

Leipzig

Lübeck

Mannheim

München

Nuremberg

Siegen

Deurne

Ewijk

Geleen

Lichtenvoorde

Oude Pekela

Rijswijk

Roelofarendsveen

Rotterdam

Wildervank

Gdansk

Gniewkowo

Kamieniec Ząbkowicki

Katowice

Libiąż

Lodz

Oława

Poznan

Płock

Skierniewice

Tarnów

Moscow

Perm

Saint Petersburg

Belgrade

Niš

Niška Banja

Zemun

Bratislava

Galanta

Levice

Lučenec

Rimavská Sobota

Boden

Gothenburg

Luleå

Lund

Malmo

Örebro

Skene

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY